Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane vs Desflurane for AKI in Liver Resection
NCT02174575Phase 4Withdrawn
- Sponsor
- Tokyo Medical and Dental University
- Start
- Jul 2014
- Primary completion
- May 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of desflurane in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and gallbladder neoplasms (2 arms), sponsored by Tokyo Medical and Dental University. Primary endpoint: Postoperative acute kidney injury. Planned start Jul 2014; status: withdrawn.
02
Drugs
desflurane
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gallbladder neoplasms
Beyond the preview
Go deeper on NCT02174575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174575.